Serum Autotaxin Concentrations Reflect Changes in Liver Stiffness and Fibrosis After Antiviral Therapy in Patients with Chronic Hepatitis C

Overview

Journal Hepatol Commun

Specialty Gastroenterology

Date 2018 Sep 12

PMID 30202824

Citations 4

Authors

Wataru Ando

Hiroaki Yokomori

Fumihiko Kaneko

Mana Kaneko

Koji Igarashi

Hidekazu Suzuki

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to determine whether serum autotaxin concentrations reflect liver stiffness in patients with chronic hepatitis C virus (HCV) treated with direct-acting antiviral agents. Adult patients with chronic HCV were enrolled from January 2016 to August 2017. Autotaxin concentrations in these patients were compared with those of a control group consisting of healthy individuals. Liver stiffness was determined by transient elastography. The relationship between fibrosis markers and fibrosis scores was evaluated before and after treatment. Data from 155 HCV patients and 56 control subjects were analyzed. Autotaxin concentrations were significantly higher in HCV patients with liver stiffness scores less than or equal to 7.4 kPa versus controls. Autotaxin concentrations at the end of treatment and beyond were significantly lower than those prior to treatment. Pretreatment and posttreatment autotaxin concentrations in male and female patients with liver stiffness scores greater than 14.9 kPa changed significantly ( < 0.01 and < 0.01, respectively). From the start of treatment to 6 months following treatment, the fibrosis marker/liver stiffness score ratios changed as follows: autotaxin: 0.189 (95% confidence interval [CI]: 0.169-0.209) to 0.191 (95% CI: 0.166-0.216; = 0.88); agglutinin-positive Mac-2-binding protein: 0.294 (95% CI: 0.256-0.332) to 0.223 (95% CI: 0.191-0.255; < 0.001); hyaluronic acid: 19.05 (95% CI: 14.29-23.81) to 13.92 (95% CI: 11.16-16.70; = 0.044); and type IV collagen 7S: 0.560 (95% CI: 0.515-0.604) to 0.546 (95% CI: 0.497-0.895; = 0.052). : Autotaxin concentrations reflect liver stiffness before and after antiviral treatment in patients with chronic HCV infection.

Citing Articles

Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.

Pastrovic F, Novak R, Grgurevic I, Hrkac S, Salai G, Zarak M PLoS One. 2024; 19(4):e0301416.

PMID: 38603681 PMC: 11008873. DOI: 10.1371/journal.pone.0301416.

A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis.

Booijink R, Salgado-Polo F, Jamieson C, Perrakis A, Bansal R EMBO Mol Med. 2022; 14(9):e16333.

PMID: 35833384 PMC: 9449594. DOI: 10.15252/emmm.202216333.

Autotaxin loss accelerates intestinal inflammation by suppressing TLR4-mediated immune responses.

Kim S, Howe C, Mitchell J, Choo J, Powers A, Oikonomopoulos A EMBO Rep. 2020; 21(10):e49332.

PMID: 32875703 PMC: 7534615. DOI: 10.15252/embr.201949332.

Usefulness of autotaxin for the complications of liver cirrhosis.

Shao X, Uojima H, Setsu T, Okubo T, Atsukawa M, Furuichi Y World J Gastroenterol. 2020; 26(1):97-108.

PMID: 31933517 PMC: 6952300. DOI: 10.3748/wjg.v26.i1.97.

References

Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X . Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2005; 55(3):403-8. PMC: 1856085. DOI: 10.1136/gut.2005.069153. View

Vrancken K, Paeshuyse J, Liekens S . Angiogenic activity of hepatitis B and C viruses. Antivir Chem Chemother. 2011; 22(4):159-70. DOI: 10.3851/IMP1987. View

George S, Bacon B, Brunt E, Mihindukulasuriya K, Hoffmann J, Di Bisceglie A . Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2008; 49(3):729-38. PMC: 2731713. DOI: 10.1002/hep.22694. View

Salcedo X, Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S, Borque M . The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology. 2005; 42(3):696-701. DOI: 10.1002/hep.20828. View

Yanase M, Ikeda H, Matsui A, Maekawa H, Noiri E, Tomiya T . Lysophosphatidic acid enhances collagen gel contraction by hepatic stellate cells: association with rho-kinase. Biochem Biophys Res Commun. 2000; 277(1):72-8. DOI: 10.1006/bbrc.2000.3634. View

Moolenaar W . LPA: a novel lipid mediator with diverse biological actions. Trends Cell Biol. 1994; 4(6):213-9. DOI: 10.1016/0962-8924(94)90144-9. View

Ikeda H, Yatomi Y, Yanase M, Satoh H, Nishihara A, Kawabata M . Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem Biophys Res Commun. 1998; 248(2):436-40. DOI: 10.1006/bbrc.1998.8983. View

Wang J, Changchien C, Hung C, Eng H, Tung W, Kee K . FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2009; 44(5):439-46. DOI: 10.1007/s00535-009-0017-y. View

Enooku K, Uranbileg B, Ikeda H, Kurano M, Sato M, Kudo H . Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels. PLoS One. 2016; 11(9):e0161825. PMC: 5008774. DOI: 10.1371/journal.pone.0161825. View

10.

Benesch M, Ko Y, McMullen T, Brindley D . Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions. FEBS Lett. 2014; 588(16):2712-27. DOI: 10.1016/j.febslet.2014.02.009. View

11.

Nishimura S, Nagasaki M, Okudaira S, Aoki J, Ohmori T, Ohkawa R . ENPP2 contributes to adipose tissue expansion and insulin resistance in diet-induced obesity. Diabetes. 2014; 63(12):4154-64. DOI: 10.2337/db13-1694. View

12.

Elpek G . Angiogenesis and liver fibrosis. World J Hepatol. 2015; 7(3):377-91. PMC: 4381164. DOI: 10.4254/wjh.v7.i3.377. View

13.

Shimizu I, Omoya T, Takaoka T, Wada S, Wada H, Taoka M . Serum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy. J Gastroenterol Hepatol. 2001; 16(2):196-201. DOI: 10.1046/j.1440-1746.2001.02402.x. View

14.

Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J . The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res. 2009; 83(2):127-34. DOI: 10.1016/j.antiviral.2009.04.002. View

15.

Wunsch E, Krawczyk M, Milkiewicz M, Trottier J, Barbier O, Neurath M . Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases. Sci Rep. 2016; 6:30847. PMC: 4978954. DOI: 10.1038/srep30847. View

16.

Shah A, Lydecker A, Murray K, Tetri B, Contos M, Sanyal A . Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7(10):1104-12. PMC: 3079239. DOI: 10.1016/j.cgh.2009.05.033. View

17.

Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J . Angiogenesis in liver disease. J Hepatol. 2009; 50(3):604-20. DOI: 10.1016/j.jhep.2008.12.011. View

18.

di Bonzo L, Novo E, Cannito S, Busletta C, Paternostro C, Povero D . Angiogenesis and liver fibrogenesis. Histol Histopathol. 2009; 24(10):1323-41. DOI: 10.14670/HH-24.1323. View

19.

Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F . The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One. 2017; 12(8):e0182710. PMC: 5552231. DOI: 10.1371/journal.pone.0182710. View

20.

Kremer A, Bolier R, Dixon P, Geenes V, Chambers J, Tolenaars D . Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. J Hepatol. 2014; 62(4):897-904. DOI: 10.1016/j.jhep.2014.10.041. View